Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
1.550
-0.050 (-3.13%)
At close: Mar 6, 2026, 4:00 PM EST
1.540
-0.010 (-0.65%)
After-hours: Mar 6, 2026, 6:03 PM EST
Acrivon Therapeutics Stock Forecast
ACRV's stock price has decreased by -72.22% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Acrivon Therapeutics stock have an average target of 13, with a low estimate of 8.00 and a high estimate of 19. The average target predicts an increase of 738.71% from the current stock price of 1.55.
Analyst Consensus: Buy
* Price targets were last updated on Jan 9, 2026.
Analyst Ratings
The average analyst rating for Acrivon Therapeutics stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 1 | 1 | 1 | 1 |
| Buy | 4 | 3 | 3 | 4 | 4 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 5 | 5 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $6 → $8 | Buy | Maintains | $6 → $8 | +416.13% | Jan 9, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $19 | Strong Buy | Reiterates | $19 | +1,125.81% | Nov 25, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $9 → $8 | Buy | Maintains | $9 → $8 | +416.13% | Aug 14, 2025 |
| Jones Trading | Jones Trading | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | May 16, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $10 → $9 | Buy | Maintains | $10 → $9 | +480.65% | May 15, 2025 |
Financial Forecast
Revenue This Year
147.90K
Revenue Next Year
1.34M
from 147.90K
Increased by 805.34%
EPS This Year
-2.05
from -2.38
EPS Next Year
-1.94
from -2.05
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1.2M | 11.0M | ||||
| Avg | 147,900 | 1.3M | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | 7,354.4% | ||||
| Avg | - | 805.3% | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.03 | -1.50 | ||||
| Avg | -2.05 | -1.94 | ||||
| Low | -2.01 | -2.60 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.